<DOC>
	<DOC>NCT00750919</DOC>
	<brief_summary>This trial is a 26-week, open label extension trial to investigate safety and explore efficacy of esmertazapine in participants with insomnia who completed protocol 21106/P05701/MK-8265-002 (NCT00631657).</brief_summary>
	<brief_title>Twenty-six Week Extension Trial of Org 50081 (Esmirtazapine) in Outpatients With Chronic Primary Insomnia (176003/P05721/MK-8265-007)</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Mental Disorders</mesh_term>
	<mesh_term>Psychotic Disorders</mesh_term>
	<mesh_term>Sleep Wake Disorders</mesh_term>
	<mesh_term>Parasomnias</mesh_term>
	<mesh_term>Sleep Initiation and Maintenance Disorders</mesh_term>
	<mesh_term>Dyssomnias</mesh_term>
	<mesh_term>Sleep Disorders, Intrinsic</mesh_term>
	<mesh_term>Mirtazapine</mesh_term>
	<criteria>Sign written informed consent Completed clinical trial 21106/P05701/MK8265002 Any (serious) adverse event, medical condition or required concomitant medication deemed relevant for exclusion in trial 21106/P05071/MK8265002 as judged by the investigator Were significantly non compliant with protocol criteria and procedures of trial 21106/P05701/MK8265002, as judged by the investigator Pregnancy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>July 2015</verification_date>
</DOC>